

A woman with dark hair, wearing red-rimmed glasses and a white lab coat, is smiling slightly while holding a pipette. She is in a laboratory setting with various equipment and shelves in the background. The image is overlaid with a large, diagonal, semi-transparent blue and white geometric pattern.

# ARIX

INVESTING IN LIFE  
CHANGING INNOVATION

ARIX BIOSCIENCE PLC (LSE:ARIX)  
INTERIM RESULTS  
SIX MONTHS ENDED 30 JUNE 2023

# DISCLAIMER

This presentation has been prepared by Arix Bioscience plc ("the "Company") and is published solely for information purposes. The contents of this presentation have not been independently verified or approved and is subject to material updating, revision and further amendment. This presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 and therefore it is being delivered for information purposes only to a very limited number of persons and companies who are persons who have professional experience in matters relating to investments and who fall within the category of person set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are otherwise permitted to receive it. Any other person who receives this presentation should not rely or act upon it. By accepting this presentation and not immediately returning it, the recipient represents and warrants that they are a person who falls within the above description of persons entitled to receive this presentation. This presentation and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.

This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any security, nor a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. No representation, warranty or other assurance, either express or implied, is provided in relation to the accuracy, fairness, completeness or reliability of the information contained herein or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers, including any talks given by presenters and any question and answer sessions (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its directors, officers, agents, associates, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this presentation.

The matters referred to in this presentation may (in whole or in part) constitute inside information for the purposes of the UK version of Regulation (EU) No 596/2014 which has effect in English law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). Without limiting the obligations imposed under MAR, by receiving this presentation you agree that you must not deal in (or encourage another person to deal in) the Company's shares or securities or base any behaviour on such information until such information has ceased to be inside information for the purposes of MAR.

This presentation may contain certain "forward-looking" statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. Such statements reflect our intentions, beliefs or current expectations or views on, among other things, our markets, activities, projections, objectives, prospects, operations, performance, financial condition, growth, strategies and the industry in which the Company operates. Such 'forward-looking' statements can sometimes, but not always, be identified by their reference to a date or point in the future or the use of 'forward-looking' terminology, including terms such as 'believes', 'estimates', 'anticipates', 'expects', 'forecasts', 'intends', 'due', 'plans', 'projects', 'goal', 'outlook', 'schedule', 'target', 'aim', 'may', 'likely to', 'will', 'would', 'could', 'should' or similar expressions or in each case their negative or other variations or comparable terminology.

By their nature, forward-looking statements involve inherent risks, assumptions and uncertainties because they relate to future events and circumstances which may or may not occur and may be beyond our ability to predict, qualify and/or quantify or control. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as of the date that they are made and no representation or warranty is given in relation to them (whether by the Company or any of its directors, officers, agents, associates, employees or advisers), including as to their completeness or accuracy or the basis on which they were prepared.

Other than in accordance with our legal and regulatory obligations (including under the UK Financial Conduct Authority's Listing Rules, the Disclosure Rules and Transparency Rules and MAR), the Company does not undertake to update any forward-looking statements to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based after the date of this presentation.

Information contained in this presentation relating to the Company or its share price or the yield on its shares are not guarantees of and should not be relied upon as an indicator of future performance. Nothing in this presentation should be construed as a profit forecast, profit estimate or a guide as to the performance, financial or otherwise, of the Company whether in the current or any future financial year.

Neither the issue of this presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation which may become apparent.

This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, associates, employees or advisers. Each party to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates, projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

The distribution of this presentation in jurisdictions other than the UK may be restricted by law and regulation and therefore any persons who are subject to the laws of any jurisdiction other than the UK should inform themselves about, and observe, any applicable requirements. Any failure to comply with these requirements may constitute a violation of the laws of the relevant jurisdiction.

This presentation has been prepared for the purpose of complying with English law and the City Code on Takeovers and Mergers and the information disclosed may not be the same as that which would have been disclosed if this presentation had been prepared in accordance with the laws of jurisdictions outside the UK.

All opinions expressed in this presentation are subject to change without notice and may differ from opinions expressed elsewhere.

By receiving this document, you agree to be bound by the restrictions in this disclaimer.

# AGENDA

- » Strategic Review Update
- » Financial Results HY 2023
- » Portfolio Update
- » Summary
- » Q&A
- » Glossary







ARIX

# STRATEGIC REVIEW UPDATE

# STRATEGIC REVIEW UPDATE

Strategic review commenced in July 2023, including consideration of:

- Investment and realisation strategies;
- Capital allocation and shareholder returns policies;
- A tax-efficient wind-down of the Company

- » Prevailing unfavourable market conditions and sustained discount to NAV lead to strategic review
- » A number of options remain under active consideration and the Board is evaluating these in conjunction with its advisers
- » A conclusion to the process will be announced soon

## BOARD SPECIAL COMMITTEE



**Peregrine Moncreiffe**

Non-Executive Chairman



**Robert Lyne**

Chief Executive Officer



**Debra Barker MD**

Senior Independent Director



**Andrew Smith**

Non-Executive Director

# ARIX BOARD OF DIRECTORS

## Arix Investment Committee Members



### » Peregrine Moncreiffe

Non-Executive Chairman

*30+ years experience in investment, most recently Chairman of North Atlantic Smaller Companies Investment Trust alongside Director at Metage Funds*



### » Robert Lyne

Chief Executive Officer

*Previously COO & General Counsel at Arix. 10 years' experience in listed venture capital and worked on 80+ VC financings and transactions. Broad experience of public company governance.*



### » Debra Barker MD

Senior Independent Director

*More than 25 years' senior experience in major pharmaceutical companies. Currently NED of public biotech companies: Destiny Pharma, BergenBio and CureVac.*



### » Isaac Kohlberg

Non-Executive Director

*Senior Associate Provost and Chief Technology Development Officer at Harvard University. Distinguished career protecting and commercialising IP for leading universities and research institutions*



### » Maureen O'Connell

Non-Executive Director

*Global business executive, formerly Senior Independent Director of Sucampo Pharmaceuticals and prior to that CFO of Scholastic Corporation*



### » Andrew Smith

Non-Executive Director

*Executive leader with over 30 years' international experience within the bio-pharma sectors. Current CFO of Santhera Pharma and previously CFO of Allegra Therapeutics and Sucampo Pharmaceuticals*

# KEY TEAM MEMBERS

## Investment Team



### » Tassos Konstantinou

#### Managing Director

*Previously an investment manager at IP Group, where he led several new investments and served on the board of privately held biotech companies*



### » Felix Breyer PhD

#### Associate

*Felix completed his PhD in biochemistry at University College London and joined Arix in 2021 where he now holds several Board Observer roles*



### » Roy Bartel-Taverner

#### Analyst

*Financial and scientific background having worked in equity research at UBS as well as being a trained medical doctor*



### » Laura Craig

#### Investor Relations Officer

*Responsible for the shareholder relations and communications alongside internal operations of Arix*



### » Tom Davidson

#### Finance Director

*Tom spent nearly a decade at Oakley Capital, a pan-European PE and VC group where he was most recently Finance Director with oversight of the internal finance and accounting operations teams*

## Finance & Operations





ARIX

# INTERIM FINANCIAL RESULTS



# INTERIM RESULTS HIGHLIGHTS 2023

## PERFORMANCE



**NAV of £239m - 185p per share**

- » Increase in NAV of £13m from £226m at YE Dec 2022
- » £16.8m invested into new listed investments in the period
- » Value of listed portfolio increased to £68m (31 Dec 2022: £45m)
- » £13.5m invested into unlisted portfolio in the period
- » Value of unlisted portfolio, £66.2m (31 Dec 2022: £54.8m)


## CAPITAL



**£101m cash at 30 June 2023**

- » Arix co-led \$50m Series B round for Evommune, investing £6.6m
- » Harpoon announced \$25m private placement in which Arix participated with a £2.9m investment
- » Successful progress of Sorriso enabled £4.0m draw down on second tranche of Series A
- » Unrealised gain of £3.5m in POP against cost to date

## PORTFOLIO



**Clinical and operational progress across portfolio's**

- » Disc Medicine raised total gross proceeds of \$220m providing runway into 2026
- » Closing of TwelveBio acquisition by Ensoma in February as well as \$50m Series B extension in May took Ensoma's total round to \$135m
- » Reverse merger of Enliven with Imara to create Nasdaq listed company alongside \$165m raise
- » Interim data readouts across the portfolio showing progress is on track

# GROSS PORTFOLIO PERFORMANCE IN THE PERIOD



**GPV at 30 June 2023:  
£134.4m**

» **£36.5m deployed in the period**

- £20.1m invested into Core Portfolio: Ensoma, Evommune, Harpoon, Sorriso and Disc
- Public Opportunities Portfolio (POP) accounted for £16.4m of investment

» **£17.7m realised in the period**


- Trading of listed assets including Disc and POP
- £6.2m of Ensoma equity in exchange for Twelve Bio

» **£19.9m net upward revaluation**

- Positive performance in listed portfolio

# NAV BREAKDOWN: CASH / PUBLIC / PRIVATE / OTHER

NAV: £239m\* (185p per share)



■ Cash ■ Public ■ Private ■ Other

» 42%  
of the NAV is cash

» 29%  
of the NAV is in listed companies,  
including both POP and Core Portfolio  
companies valued at market prices


» 28%  
of the NAV is in our Core Portfolio of private  
companies, valued using The International PE  
and VC Valuation Guidelines

» 2%  
of the NAV is in other interests



# NAV PER SHARE BREAKDOWN

NAV per share performance against listed share price\*



» Persistent discount to NAV over prolonged period

» Current share price underpinned by cash holdings

# Financial Review

NAV of £239m (185p); capital pool of £101m

Investment	31 Dec 2022 £m	Investment in Period £m	Realisations in Period £m	Impairment in Period £m	Change in Valuation £m	FX Movement £m	30 June 2023 £m	Equity Interest %	Fully Funded %
<b>Core Portfolio</b>									
<b>Unlisted</b>									
Artios	24.9	-	-	-	-	-	24.9	8.8%	8.8%
Depixus	8.2	-	-	-	-	(0.2)	8.0	14.2%	14.2%
Ensoma	7.5	6.2	-	-	-	(0.7)	13.0	6.0%	6.0%
Evommune	-	6.6	-	-	-	(0.2)	6.4	3.4%	3.5%
Harpoon Redeemable Preference Shares **	-	2.9	-	-	-	(0.1)	2.8	-	-
Sorriso	6.6	4.0	-	-	-	(0.4)	10.2	26.1%	26.1%
Twelve Bio	5.0	-	(6.2)	-	1.2	-	-	-	-
STipe	1.3	-	-	(1.2)	(0.1)	-	-	-	-
Amplix	1.3	-	-	-	(0.3)	(0.1)	0.9	-	-
<b>Unlisted total</b>	<b>54.8</b>	<b>19.7</b>	<b>(6.2)</b>	<b>(1.2)</b>	<b>0.8</b>	<b>(1.7)</b>	<b>66.2</b>	<b>-</b>	<b>-</b>
<b>Listed</b>									
Aura	13.1	-	-	-	2.2	(0.6)	14.7	4.0%	4.0%
Disc Medicine	9.0	0.4	(1.1)	-	12.7	(0.3)	20.7	2.6%	2.6%
Harpoon Therapeutics	1.3	-	-	-	-	(0.1)	1.2	5.8%	5.8%
Imara / Enliven ***	7.9	-	-	-	1.9	(0.4)	9.4	1.4%	1.4%
<b>Public Opportunities Portfolio</b>	<b>13.5</b>	<b>16.4</b>	<b>(10.4)</b>	<b>-</b>	<b>3.5</b>	<b>(0.9)</b>	<b>22.1</b>	<b>-</b>	<b>-</b>
<b>Listed total</b>	<b>44.8</b>	<b>16.8</b>	<b>(11.5)</b>	<b>-</b>	<b>20.3</b>	<b>(2.3)</b>	<b>68.1</b>	<b>-</b>	<b>-</b>
Legacy Assets	0.1	-	-	-	-	-	0.1	-	-
<b>Gross Portfolio</b>	<b>99.7</b>	<b>36.5</b>	<b>(17.7)</b>	<b>(1.2)</b>	<b>21.1</b>	<b>(4.0)</b>	<b>134.4</b>	<b>-</b>	<b>-</b>
<b>Other interests</b>	<b>3.0</b>	<b>-</b>	<b>(0.2)</b>	<b>-</b>	<b>-</b>	<b>(0.1)</b>	<b>2.7</b>	<b>-</b>	<b>-</b>
<b>Total Investments</b>	<b>102.7</b>	<b>36.5</b>	<b>(17.9)</b>	<b>(1.2)</b>	<b>21.1</b>	<b>(4.1)</b>	<b>137.1</b>	<b>-</b>	<b>-</b>












ARIX

# PORTFOLIO REVIEW











# PORTFOLIO COMPANY OVERVIEW

Breakdown of Core Portfolio\*







Portfolio Company	Therapeutic Area	Company Stage	Expected Milestone	Holding %	Holding £
Private					
	Oncology	Clinical	Safety / efficacy data	8.8%	£24.9m
	Genetic Diseases	Development	Proof of application	14.2%	£8.0m
	Immunology	Clinical	Safety / efficacy data	3.4%	£6.4m
	Genetic Diseases	Pre-clinical	IND Filing	6.0%	£13.0m
	Immunology	Clinical	CTA approval	26.1%	£10.2m
Public					
	Oncology	Clinical	Efficacy data	4.0%	£14.7m
	Haematology	Clinical	Safety / efficacy data	2.6%	£20.7m
	Oncology	Clinical	Safety / efficacy data	1.4%	£9.4m
	Oncology	Clinical	Efficacy data	5.8%	£4.0m

\*Figures as at 30 June 2023

# CLINICAL AND OPERATIONAL HIGHLIGHTS MADE IN 2023

	Oncology	<ul style="list-style-type: none"> <li>&gt; Initiated a Ph2 randomised trial for ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer</li> <li>&gt; Launched a national project with IUCT-Oncopole, a cancer care, research and training centre in Toulouse, France, to overcome resistance to therapies for familial breast cancer</li> </ul>
	Immunology	<ul style="list-style-type: none"> <li>&gt; Raised \$50 million Series B in April with Arix investing £6.6 million. In June closed an additional \$7.5m into the round bringing the total raised to \$57.5m</li> </ul>
	Genetic Diseases	<ul style="list-style-type: none"> <li>&gt; \$85 million financing co-led by Arix for Ensoma along with acquisition of Twelve Bio</li> <li>&gt; Closed Series B extension financing, raising a further \$50 million, bringing the total round to \$135 million.</li> </ul>
	Immunology	<ul style="list-style-type: none"> <li>&gt; Good progress preparing for initiation of Ph 1 clinical trial in 2023</li> <li>&gt; Progress enabled draw down on second tranche of Series B (£4.0m from Arix)</li> </ul>
	Oncology	<ul style="list-style-type: none"> <li>&gt; Positive interim Ph 2 safety and efficacy data of bel-sar in patients with early-stage Choroidal Melanoma with suprachoroidal (SC) administration. The interim data provides strong confidence to support the launch of the global Phase 3 trial which is on track to dose the first patient this year</li> <li>&gt; Bel-sar granted Fast Track Designation by the FDA for the treatment of Choroidal Metastasis</li> </ul>
	Haematology	<ul style="list-style-type: none"> <li>&gt; Raised \$220 million providing runway into 2026</li> <li>&gt; Positive initial data from ongoing Ph 2 trial of Bitopertin in patients with Erythropoietic Protoporphyria</li> <li>&gt; Initiation of Ph 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia who have failed corticosteroid treatment</li> <li>&gt; Enrolment of patients in two separate Ph 1b/2 studies for DISC-0974, one in patients with NDD-CKD and one in patients with myelofibrosis and anaemia</li> <li>&gt; Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera</li> </ul>
	Oncology	<ul style="list-style-type: none"> <li>&gt; Enliven entered the public market via reverse merger with Imara Inc. (previously Nasdaq: IMRA).</li> <li>&gt; Completed a \$165 million private placement with participation from new and existing investors</li> <li>&gt; Progress ELVN-001 and ELVN-002, through dose escalation in Ph 1 trials, with initial data for both programs expected in 2024</li> </ul>
	Oncology	<ul style="list-style-type: none"> <li>&gt; Closed private placement to raise \$25 million in which Arix invested £2.9 million to extend cash runway into H2 2024</li> <li>&gt; Completed enrolment of patients in Ph 1 study of HPN217 in Relapsed/Refractory Multiple Myeloma</li> <li>&gt; Dosed first patients with small cell lung cancer (SCLC) in a Ph 1/2 trial of HPN328 in combination with atezolizumab (Tecentriq®)</li> </ul>

# MULTIPLE CLINICAL CATALYSTS EXPECTED IN H2 2023 & 2024

Company	Programme/Indication	Stage	H2 2023	H1 2024	H2 2024	2024-25
	ART0380 - Advanced or Metastatic Solid Tumours	Ph1	Ph1 Safety & Tolerability Data		Ph2 data	Clinical data from multiple studies
	ART6043 – Solid Tumour	Ph1				
	ART4215 + Talazoparib – Breast Cancer	Ph1			Initial Ph2 Data	
	EVO101 – Atopic Dermatitis	Ph2	Ph2 Data			New trial initiations
	AU-011 - Choroidal Melanoma (SC)	Ph2	Ph2 data Initiation of Ph3 study		Interim Ph3 Data	
	AU-011 –Choroidal metastasis	Ph2			Initiation of Ph2 study	
	AU-011 – Non-Muscle Invasive Bladder Cancer	Ph1			Ph1 Data	
	Bitopertin – Erythropoietic Porphyrias (EPP and XLP)	Ph2	Ph2 BEACON Data	Ph2 AURORA data		Progress discovery and preclinical programmes
	Bitopertin – Diamond-Blackfan Anemia (DBA)	Ph2			Initial Ph2 DBA data	
	DISC-0974 – Anemias of myelofibrosis (MF) and chronic kidney disease (CKD)	Ph1	Initial Ph1b/2 Data		Ph2 MF & CKD data	
	ELVN-001 - Chronic Myeloid Leukemia	Ph1			Ph1a Safety / Efficacy Data	
	ELVN-002 – Lung Cancer	Ph1			Ph1a Safety / Efficacy Data	
	HPN328 – Small Cell Lung Cancer	Ph1	Ph1/2 Data			
	HPN217 – Multiple Myeloma	Ph1	Ph1/2 Data			



# PUBLIC OPPORTUNITIES PORTFOLIO

## Taking advantage of opportunities in the public markets

- » Disconnect in public and private valuations of biotech companies observed in early 2022 lead to the creation of our Public Opportunities Portfolio, "POP"
- » The investment criteria was the same as our private venture investments but offered a significant value play given unwarranted shift in sentiment against the public biotech markets
- » Liquid positions in well-funded, clinical-stage biotech companies, with near term milestones, provided a dynamic opportunity

### POP outperforms XBI by 26% since portfolio inception

The mid-September 2023 value of active POP was broadly flat at a value of \$20.8m vs a cost of \$21.6m, which was favourable to the XBI having had a 17.3% drop since POP's inception

As of mid-September we maintained out performance by 26% returning 8.8%, including realised gains and losses, against a drop in the XBI of 17.3% in the same period





ARIX

OUTLOOK

# OUTLOOK



## Arix

- » Strategy Review launched in July 2023
- » A number of options remain under active consideration
- » Significant cash balance of £101m at 30 June 2023



## Portfolio

- » Well-funded portfolio with multiple clinical and preclinical catalysts expected over the next 12-18 months





A photograph of a laboratory setting. In the foreground, a person wearing blue nitrile gloves is marking clear plastic test tubes with a red marker. The test tubes are held in a purple and grey rack. The rack has the word 'STEM' and 'D TO' visible on its side. In the background, there are various laboratory items, including a pink container and a beaker with red liquid. The image is split diagonally, with the left side showing the lab scene and the right side being white with text.

# ARIX

## Q&A



ARIX

THANK YOU

To subscribe to our mailing list please ccontact:  
[ir@arixbioscience.com](mailto:ir@arixbioscience.com)

[www.arixbioscience.com](http://www.arixbioscience.com)



# GLOSSARY OF ABBREVIATIONS



» ADC	Antibody Drug Conjugate
» NDA	New Drug Application
» IBD	Inflammatory Bowl Disease
» DDR	DNA Damage Response
» NAV	Net Asset Value
» NMIBC	Non-Muscle Invasive Bladder Cancer
» EMA	European Medicines Agency
» GPV	Gross Portfolio Value
» IND	Investigational New Drug
» Ph1	Phase 1 Trial – studies the safety of drug
» Ph2	Phase 2 Trial – studies the efficacy of drug
» Ph3	Phase 3 Trial – studies the safety, efficacy & dosing
» SCLC	Small Cell Lung Cancer

» NDD-CKD	Non-Dialysis Dependent Chronic Kidney Disease
» Bel-sar	Belzupacap Sarotalocan
» EPP	Erythropoietic Protoporphyria
» XLP	X-linked Protoporphyria
» DBA	Diamond-Blackfan Anemia
» MF	Myelofibrosis
» CKD	Chronic Kidney Disease

»

»

»

»